JP2022512863A5 - - Google Patents

Info

Publication number
JP2022512863A5
JP2022512863A5 JP2021523487A JP2021523487A JP2022512863A5 JP 2022512863 A5 JP2022512863 A5 JP 2022512863A5 JP 2021523487 A JP2021523487 A JP 2021523487A JP 2021523487 A JP2021523487 A JP 2021523487A JP 2022512863 A5 JP2022512863 A5 JP 2022512863A5
Authority
JP
Japan
Prior art keywords
antibody
composition according
seq
inhibitor
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523487A
Other languages
English (en)
Japanese (ja)
Other versions
JP7499760B2 (ja
JP2022512863A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059446 external-priority patent/WO2020092937A1/en
Publication of JP2022512863A publication Critical patent/JP2022512863A/ja
Publication of JP2022512863A5 publication Critical patent/JP2022512863A5/ja
Application granted granted Critical
Publication of JP7499760B2 publication Critical patent/JP7499760B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523487A 2018-11-02 2019-11-01 脳損傷を治療するための組成物及び方法 Active JP7499760B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754750P 2018-11-02 2018-11-02
US62/754,750 2018-11-02
PCT/US2019/059446 WO2020092937A1 (en) 2018-11-02 2019-11-01 Compositions and methods for treating brain injury

Publications (3)

Publication Number Publication Date
JP2022512863A JP2022512863A (ja) 2022-02-07
JP2022512863A5 true JP2022512863A5 (https=) 2022-12-20
JP7499760B2 JP7499760B2 (ja) 2024-06-14

Family

ID=70459352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523487A Active JP7499760B2 (ja) 2018-11-02 2019-11-01 脳損傷を治療するための組成物及び方法

Country Status (8)

Country Link
US (2) US20200140533A1 (https=)
EP (1) EP3873525B1 (https=)
JP (1) JP7499760B2 (https=)
AU (1) AU2019370485B2 (https=)
CA (1) CA3118453A1 (https=)
ES (1) ES3015004T3 (https=)
MX (1) MX2021004819A (https=)
WO (1) WO2020092937A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
AU2021278819A1 (en) * 2020-05-05 2022-11-24 Annexon, Inc. Compositions and methods for treating epilepsy
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
IL300376A (en) * 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
US20240420490A1 (en) * 2021-10-19 2024-12-19 Denali Therapeutics Inc. Microglial cell morphometry
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
CN121197154A (zh) * 2025-11-13 2025-12-26 首都医科大学附属北京天坛医院 Mac-1激动剂在制备治疗和/或缓解脑出血药物中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
ES2447844T3 (es) 2008-04-03 2014-03-13 Vib Vzw Anticuerpos de dominio individual capaces de modular la actividad BACE1
AU2009283889A1 (en) * 2008-08-20 2010-02-25 The Trustees Of Columbia University In The City Of New York Complement inhibitors for treatment of injury from intracerebral hemorrhage
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
EP3722320A3 (en) * 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP2997045A4 (en) * 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
EP3004170A1 (en) 2013-05-28 2016-04-13 VIB vzw Single domain antibodies against sod1 and their use in medicine
DK3019240T3 (da) * 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
SI3215527T1 (sl) * 2014-11-05 2025-04-30 Annexon, Inc. Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
SG11201900123TA (en) * 2016-07-19 2019-02-27 Annexon Inc Compositions and methods for treating frontotemporal dementia

Similar Documents

Publication Publication Date Title
JP2022512863A5 (https=)
US20210230269A1 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
JP7837375B2 (ja) ピログルタメートアミロイド－βに対する抗体及びその使用
JP6333174B2 (ja) 抗ｔｉｅ２抗体およびその使用
JP7173618B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
JP7455388B2 (ja) 抗ｄｌｌ３抗体及びその使用
KR20200129116A (ko) 항-클라우딘 18.2 항체 및 이의 용도
WO2018081642A1 (en) Anti-apoe antibodies
JP2019505166A5 (https=)
JP2019504615A5 (https=)
CN115925952A (zh) 抗叶酸受体1抗体及其用途
JP2022513050A5 (https=)
CN114729036B (zh) 抗干细胞因子抗体及其使用方法
JP2023524819A5 (https=)
CN111886024B (zh) 抗tip-1抗体及其用途
CN115947849A (zh) 双特异性蛋白
JP2025539937A (ja) 抗ｐａｐｐ－ａ抗体及びその使用方法
JP2024534313A (ja) 抗ｃｇｒｐ抗体の投薬及びスクリーニング方法
CN120058937B (zh) 一种靶向lgr4的纳米抗体nb21及其在抗肥胖治疗中的应用
US20250163136A1 (en) Anti-transthyretin (ttr) binding proteins and uses thereof
CN120035606A (zh) 一种治疗实体瘤的方法
CN120118184A (zh) 靶向Tau的特异性结合蛋白及其应用
CN119677537A (zh) 用于治疗狼疮性肾炎的组合物和方法
JP2025503545A (ja) ハンチントン病を治療するための組成物及び方法
HK40114489A (zh) 用於治疗亨廷顿氏病的组合物和方法